Literature DB >> 6277936

Locking of hormone in the beta-adrenergic receptor by attack on a sulfhydryl in an associated component.

M Korner, C Gilon, M Schramm.   

Abstract

Isoproterenol incubated with turkey erythrocyte membranes causes exposure of a specific --SH in a component associated with the beta-adrenergic receptor, presumably in the guanyl nucleotide binding protein. Addition of a reagent which interacts with that specific --SH results in trapping of the hormone in the receptor. As a consequence, the number of hormone binding sites and the function of the receptor are both drastically reduced. Extended incubation at alkaline pH or addition of GDP or GTP at high concentration reactivate the beta-adrenergic receptor. Labeled antagonist binding as well as function of the receptor in activating an adenylate cyclase system are restored. The findings suggest that the normal interaction of the hormone-receptor complex with the guanyl nucleotide binding protein involves a conformational change which transiently locks the hormone in the receptor. GTP releases the tight interaction while addition of an --SH reagent traps the ternary complex of hormone-receptor-guanyl nucleotide binding protein in the locked conformation. Since the components of different hormone-activated adenylate cyclase systems were shown to be interchangeable, it seems likely that the hormone-receptor interaction with the guanyl nucleotide binding protein, as revealed in the present study, is not limited to beta-adrenergic receptor systems.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6277936

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Agonist-mediated conformational changes of beta-adrenoceptors could occur independent of functional coupling to Ns.

Authors:  Y Severne; L Kanarek; G Vauquelin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-03       Impact factor: 3.000

2.  The beta-adrenoceptor-adenylate cyclase complex. From model to biochemical reality.

Authors:  A P Ijzerman; H Timmerman
Journal:  Pharm Weekbl Sci       Date:  1986-08-22

3.  Ligand-induced association between the T-cell antigen receptor and two glycoproteins.

Authors:  J D Fraser; M A Goldsmith; A Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Radioreceptor binding reveals the potencies of N,N-disubstituted 2-aminotetralins as D2 dopamine agonists.

Authors:  P M Beart; C J Cook; M Cincotta; D J de Vries; P Tepper; D Dijkstra; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

Review 5.  Reconstitution of the beta-adrenergic receptor.

Authors:  R J Lefkowitz; R A Cerione; J Codina; L Birnbaumer; M G Caron
Journal:  J Membr Biol       Date:  1985       Impact factor: 1.843

6.  A redox cycling model for the action of beta-adrenoceptor agonists.

Authors:  P W Kühl
Journal:  Experientia       Date:  1985-09-15

7.  Trapping of the beta-adrenergic receptor in the hormone-induced state.

Authors:  G Neufeld; S Steiner; M Korner; M Schramm
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

8.  Reconstitution of beta-adrenergic receptors in lipid vesicles: affinity chromatography-purified receptors confer catecholamine responsiveness on a heterologous adenylate cyclase system.

Authors:  R A Cerione; B Strulovici; J L Benovic; C D Strader; M G Caron; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

9.  Influence of the beta-adrenergic receptor concentration on functional coupling to the adenylate cyclase system.

Authors:  Y Severne; D Coppens; S Bottari; M Riviere; R Kram; G Vauquelin
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

10.  Different effects of N-ethylmaleimide on M1 and M2 muscarine receptors in rat brain.

Authors:  D D Flynn; L T Potter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.